Next Generation Immunotherapies Market Forecast 2025-2034: Analysing Major Trends, Opportunities, and Growth Drivers

Which drivers are expected to have the greatest impact on the over the next generation immunotherapies market's growth?
The increasing prevalence of cancer is expected to drive the growth of the next-generation immunotherapies market. Cancer's rising prevalence is attributed to factors such as aging, environmental exposures, lifestyle changes, and better detection methods. Next-generation immunotherapies, which boost the body's immune response against cancer, offer more targeted, durable, and personalized treatments. For instance, in May 2024, the National Cancer Institute projected that the global number of new cancer cases will reach 29.9 million by 2040, up from 20 million in 2022. This surge in cancer cases is expected to accelerate the demand for next-generation immunotherapies, driving the growth of this market.

Get Your Next Generation Immunotherapies Market Report Here:
https://www.thebusinessresearchcompany.com/report/next-generation-immunotherapies-global-market-report

What is the future CAGR of the next generation immunotherapies market, and how will it impact industry expansion?
The next-generation immunotherapies market has grown rapidly, increasing from $133.81 billion in 2024 to $150.54 billion in 2025 at a CAGR of 12.5%. Growth has been fueled by the increasing prevalence of cancer, rising R&D investments, government initiatives, higher healthcare spending, and the expansion of treatment indications.

The next-generation immunotherapies market is set for rapid expansion, reaching $238.04 billion by 2029, with a CAGR of 12.1%. This growth will be fueled by the increasing prevalence of cancer, rising healthcare expenditures, higher adoption of chimeric antigen receptor (CAR) T-cell therapy, a growing burden of chronic diseases, and significant research in next-generation drug development. Notable trends include a shift towards combination therapies, breakthroughs in therapeutic technologies, advancements in personalized medicine, and improvements in regulatory frameworks.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21231&type=smp

What are the most significant trends transforming the next generation immunotherapies market today?
In the next-generation immunotherapies market, companies are focusing on developing innovative therapies such as CAR T-cell therapy to treat cancers, autoimmune diseases, and infectious diseases. For instance, in January 2025, Immuneel Therapeutics Private Limited, an India-based cell and gene therapy startup, launched Qartemi, India's first CAR T-cell therapy for B-cell non-Hodgkin lymphoma. This therapy involves genetically modifying a patient's immune cells to target and destroy cancer cells, providing a highly personalized treatment approach. It offers a promising and more affordable alternative compared to global CAR T-cell therapies, giving hope to patients for whom conventional treatments have failed.

Which key market segments comprise the next generation immunotherapies market and drive its revenue growth?
The next generation immunotherapies market covered in this report is segmented -

1) By Drug Class: Monoclonal Antibodies, Antibody-Drug Conjugates - ADC's, Angiotensin-Converting Enzyme (ACE) Inhibitors, Immune Checkpoint Inhibitors
2) By Route Of Administration: Intravenous, Parenteral, Intratumoral, Subcutaneous, Oral
3) By Distribution Channel: Hospital Pharmacies, Clinical Pharmacies, Other Distribution channels

Subsegments:
1) By Monoclonal Antibodies: Anti-PD-1 Antibodies, Anti-PD-L1 Antibodies, Anti-CTLA-4 Antibodies, Anti-CD20 Antibodies, Other Monoclonal Antibodies
2) By Antibody-Drug Conjugates (ADC's): HER2-targeted ADCs, CD30-targeted ADCs, CD19-targeted ADCs, Other ADCs
3) By Angiotensin-Converting Enzyme (ACE) Inhibitors: ACE Inhibitors For Cancer Therapy, ACE Inhibitors For Other Indications
4) By Immune Checkpoint Inhibitors: PD-1 Or PD-L1 Inhibitors, CTLA-4 Inhibitors, Other Immune Checkpoint Inhibitors

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21231

What regions are at the forefront of next generation immunotherapies market expansion?
North America was the largest region in the next-generation immunotherapies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next generation immunotherapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Who are the leading players fueling growth in the next generation immunotherapies market?
Major companies operating in the next generation immunotherapies market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Incyte Corporation, BioNTech SE, Xencor Inc., Fate Therapeutics Inc., Immatics N.V., Atara Biotherapeutics Inc., Menarini Group, Alpine Immune Sciences Inc., Mereo Biopharma Group plc, Immunomic Therapeutics Inc., Indaptus Therapeutics Inc.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=21231&type=smp

What Is Covered In The Next Generation Immunotherapies Global Market Report?

•Market Size Forecast: Examine the next generation immunotherapies market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the next generation immunotherapies market for a structured understanding.
•Key Players Overview: Analyze major players in the next generation immunotherapies market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the next generation immunotherapies market.
•Segment Contributions: Evaluate how different segments drive overall growth in the next generation immunotherapies market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the next generation immunotherapies market.
•Industry Challenges: Identify potential risks and obstacles affecting the next generation immunotherapies market.
•Competitive Landscape: Review strategic developments in the next generation immunotherapies market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.